- Home
- FBLG vs LNSR Comparison
FBLG vs LNSR Comparison
Compare FBLG & LNSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBLG
- LNSR
- Stock Information
- Founded
- FBLG 2021
- LNSR 2004
- Country
- FBLG United States
- LNSR United States
- Employees
- FBLG N/A
- LNSR N/A
- Industry
- FBLG
- LNSR Medical Electronics
- Sector
- FBLG
- LNSR Health Care
- Exchange
- FBLG NYSE
- LNSR Nasdaq
- Market Cap
- FBLG 67.7M
- LNSR 63.4M
- IPO Year
- FBLG 2024
- LNSR N/A
- Fundamental
- Price
- FBLG $1.13
- LNSR $9.29
- Analyst Decision
- FBLG Strong Buy
- LNSR
- Analyst Count
- FBLG 4
- LNSR 0
- Target Price
- FBLG $13.00
- LNSR N/A
- AVG Volume (30 Days)
- FBLG 524.8K
- LNSR 107.2K
- Earning Date
- FBLG 03-04-2025
- LNSR 02-27-2025
- Dividend Yield
- FBLG N/A
- LNSR N/A
- EPS Growth
- FBLG N/A
- LNSR N/A
- EPS
- FBLG N/A
- LNSR N/A
- Revenue
- FBLG N/A
- LNSR $48,868,000.00
- Revenue This Year
- FBLG N/A
- LNSR $25.07
- Revenue Next Year
- FBLG N/A
- LNSR $24.95
- P/E Ratio
- FBLG N/A
- LNSR N/A
- Revenue Growth
- FBLG N/A
- LNSR 21.29
- 52 Week Low
- FBLG $1.06
- LNSR $2.67
- 52 Week High
- FBLG $14.70
- LNSR $12.13
- Technical
- Relative Strength Index (RSI)
- FBLG 32.20
- LNSR 42.92
- Support Level
- FBLG $1.12
- LNSR $9.66
- Resistance Level
- FBLG $1.32
- LNSR $11.80
- Average True Range (ATR)
- FBLG 0.20
- LNSR 0.95
- MACD
- FBLG -0.03
- LNSR -0.25
- Stochastic Oscillator
- FBLG 6.91
- LNSR 4.38
About FBLG FIBROBIOLOGICS INC
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.
About LNSR LENSAR Inc.
LENSAR Inc is a commercial-stage medical device company focused on designing, developing and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency and reproducibility by providing imaging, simplified procedure planning, efficient design and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The consumable portion of the system consists of a disposable patient interface device, or PID, kit and a procedure license. Each procedure on each system requires the use of a PID kit.